Trial Profile
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Natural killer cell therapy Shenzhen Hank Bioengineering Institute (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- 10 Sep 2019 Status changed from recruiting to completed.
- 01 Aug 2016 New trial record